Vetter Pharma International GmbH
Filling your clinical development needs Vetter Development Service provides expert support for your drug development projects, from inception to market launch. Our services include state-of-the-art clinical manufacturing at our facilities in Chicago and Europe, with scale-up and transfer to our large-scale manufacturing facilities. Thanks to the latest technology and innovative processes, we help increase your API yield.
Vetter Development Service provides:
• Formulation support
• Process development
• Clinical trial manufacturing
• Analytical service
• Regulatory support
Learn more (please link this)
www.vetter-pharma.com/en/services/development-service?utm_source=pte&utm_medium=text-ad&utm_content=vds&utm_campaign=products-services
Contact Details:
For US inquiries please contact +1-847-581-6888 or infoUS@vetter-pharma.com.
For Asia Pacific inquiries please contact +65-6808-7766 or infoAsiaPacific@vetter-pharma.com.
For EU and other international inquiries please contact +49-751-3700-0 or info@vetter-pharma.com.
Visit www.vetter-pharma.comfor more information
Company Details:
Company name: Vetter Pharma International GmbH
Website: www.vetter-pharma.com
E-mail: info@vetter-pharma.com
Stand/Booth number: (4.1K70)
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
